Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

A downtrend has been apparent in Minerva Neurosciences (NERV) lately. While the stock has lost 10.3% over the past four weeks, it could witness a trend reversal as a hammer chart pattern was formed in ...

The average one-year price target for Minerva Neurosciences (NasdaqCM:NERV) has been revised to $7.40 / share. This is an ...

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and ...

Minerva Neurosciences (NERV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for ...

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.